Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:01:16.825Z.
Calculation as of: 2026-10-06T19:01:16.825Z.
Quote observation: 2026-10-06T18:56:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7a9a1b17caad0ab37430e79e816a911291535ac0fb348029df9f580b63ef335
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Cadrenal Therapeutics, Inc. Common Stock
Market Cap
$3.67M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.69M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.77M
EV/Sales Ratio
N/A
TTM Avg
2126.93x
3Y Avg
1896.72x
5Y Avg
1896.72x
Market Cap
$3.53M
EV/Sales Ratio
11.62x
TTM Avg
51.17x
3Y Avg
75.53x
5Y Avg
61.28x
Market Cap
$3.49M
EV/Sales Ratio
N/A
TTM Avg
141394.83x
3Y Avg
141394.83x
5Y Avg
141394.83x
Market Cap
$3.46M
EV/Sales Ratio
N/A
TTM Avg
5.13x
3Y Avg
110.83x
5Y Avg
110.83x
Market Cap
$3.89M
EV/Sales Ratio
2.71x
TTM Avg
0.98x
3Y Avg
28.60x
5Y Avg
60.35x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cadrenal Therapeutics, Inc. Common Stock (CVKD) | $3.67M | N/A | N/A | N/A | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.69M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.58M | N/A | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.77M | N/A | 2126.93x | 1896.72x | 1896.72x |
| Evogene Ltd. (EVGN)vs › | $3.79M | N/A | 1.52x | 2.03x | 233.77x |
| Nexalin Technology, Inc. (NXL)vs › | $3.53M | 11.62x | 51.17x | 75.53x | 61.28x |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A | 141394.83x | 141394.83x | 141394.83x |
| Moolec Science S.A. (MLEC)vs › | $3.46M | N/A | 5.13x | 110.83x | 110.83x |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.89M | 2.71x | 0.98x | 28.60x | 60.35x |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.96M | N/A | 0.35x | 5.55x | 4.43x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
